Heart failure (HF) is a common and serious
comorbidity of diabetes. Oxidative stress has
been associated with the pathogenesis of
chronic diabetic complications including cardiomyopathy.
The ability of antioxidants to
inhibit injury has raised the possibility of new
therapeutic treatment for diabetic heart diseases.
Riboflavin constitutes an essential
nutrient for humans and animals and it is an
important food additive. Riboflavin, a precursor
of flavin mononucleotide (FMN) and flavin
adenine dinucleotide (FAD), enhances the
oxidative folding and subsequent secretion of
proteins. The objective of this study was to
investigate the cardioprotective effect of
riboflavin in diabetic rats. Diabetes was
induced in 30 rats by a single injection of
streptozotocin (STZ) (70 mg /kg). Riboflavin
(20 mg/kg) was orally administered to animals
immediately after induction of diabetes and
was continued for eight weeks. Rats were
examined for diabetic cardiomyopathy by left
ventricular (LV) remadynamic function.
Myocardial oxidative stress was assessed by measuring the activity of superoxide dismutase (SOD), the level of malondialdehyde (MDA) as well as heme oxygenase-1 (HO-1) protein level. Myocardial connective tissue growth factor (CTGF) level was measured by Western blot in all rats at the end of the study. In the untreated diabetic rats, left ventricular systolic pressure (LVSP) rate of pressure rose (+dp/dt), and rate of pressure decay (−dp/dt) were depressed while left ventricular enddiastolic pressure (LVEDP) was increased, which indicated the reduced left ventricular contractility and slowing of left ventricular relaxation. The level of SOD decreased, CTGF and HO-1 protein expression and MDA content rose. Riboflavin treatment significantly improved left ventricular systolic and diastolic function in diabetic rats, there were persistent increases in significant activation of SOD and the level of HO-1 protein, and a decrease in the level of CTGF. These results suggest that riboflavin treatment ameliorates myocardial function and improves heart oxidant status, whereas raising myocardial HO-1 and decreasing myocardial CTGF levels have beneficial effects on diabetic cardiomyopathy.
Riboflavin, diabetic cardiomyopathy, heme oxygenase-1.
Guoguang Wang, Department of Pathophysiology, Wannan Medical College, Wuhu 241000, China. E-mail: firstname.lastname@example.org.
Share this Article
Related Content In Heart Failure
A Personalized Approach to the Management of Congestion in Acute Heart Failure
Heart International. 2023;17(2)35-42
Heart failure (HF), a prevalent disease, is the common final pathway of several conditions, which result in the activation of numerous neurohumoral pathways. Cardiorenal interaction plays an essential role in the progression of the disease, and the use of diuretics is a cornerstone in the treatment of hypervolemic patients, especially in acute decompensated HF (ADHF).1 The […]
Integrating Palliative Care into the Management of Heart Failure with Reduced Ejection Fraction: A Practice Pearl
Heart International. 2023;17(1):5–7 DOI: https://doi.org/10.17925/HI.2023.17.1.5
Palliative care (PC) is recommended as a standard of practice for all patients with heart failure (HF) and is supported by evidence of improved patient outcomes (e.g. reduction in symptoms refractory to cardiovascular therapies and improved shared decision-making).1 PC also addresses the persistent disparity in care experienced by patients from disenfranchised groups.2 PC is often a consultative […]
Measurement of Blood Volume in Patients with Heart Failure: Clinical Relevance, Surrogates, Historical Background and Contemporary Methodology
Heart International. 2023;17(1):36–44 DOI: https://doi.org/10.17925/HI.2023.17.1.36
Heart failure (HF) is a common clinical diagnosis often requiring hospitalization secondary to patient decompensation associated with clinically determined ‘dry’ or ‘wet’ volume states. However, fluid overload is the more common basis for clinical deterioration accounting for the majority of hospitalizations.1–4 There is often a cycle of decompensation, compensation following intervention and then a recurrence of volume overload […]